Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 16 people in total — 8 received a drug called Pulmozyme (also known as dornase alfa) and 8 received a placebo (a dummy treatment with no active ingredient). The trial was looking at whether Pulmozyme, delivered directly into the sinuses after surgery, could reduce sinus disease in people with cystic fibrosis over a 12-month period. Not everyone finished the study: 5 people in the Pulmozyme group and 6 in the placebo group completed it, with 3 and 2 people respectively not completing the trial (the reasons were not detailed in the reported data). The reported data shows the following numbers across the main and secondary measurements. For sinus appearance on CT scans (scored on a 0–24 scale, where a higher number means more disease), the Pulmozyme group's score changed by 5.875 units and the placebo group's score changed by 3 units — both representing a reduction from baseline, meaning less disease was seen at one year in both groups. For the appearance of the nasal passages as assessed by a surgeon using a camera (scored 0–2, where lower is better), the Pulmozyme group's score changed by +0.2 units and the placebo group's score changed by −1 unit from baseline. On a sinusitis symptom survey (scored 0–24, where lower is better), the Pulmozyme group's score reduced by 8.5 units and the placebo group's by 3 units. For lung function — measured as how much air a person can forcefully breathe out in one second — the reported change over the year was +0.8 percentage points for the Pulmozyme group and +5.4 percentage points for the placebo group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 33735508) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Cystic Fibrosis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with cystic fibrosis through medical tests and lab results
- You are 5 years old or older
- Your lung function test shows that you can breathe out at least 40% of the normal expected amount in one second (confirm with trial site)
- You have had sinus surgery within one week of joining the trial
Who may not be able to join:
- You are pregnant
- You have had a bad reaction to or cannot tolerate a inhaled medication called Pulmozyme (also known as dornase alfa)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Computed Tomography Evidence of Less Sinus Disease; Improvement in Appearance of Nasal Passages/Sinuses
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.